Taxanes–docetaxel and cabazitaxel–are the most active chemotherapy drugs currently used
for the treatment of metastatic castration-resistant prostate cancer (mCRPC). However …

Background Once castration resistance is documented and secondary hormone therapy is
ineffective, standard treatment of metastatic prostate cancer is docetaxel, with …

BACKGROUND. Prostate cancer is the second leading cause of cancer mortality among
men in the US To the authors' knowledge, there is no proven, effective, second‐line therapy …

Background There is no proven, effective, standard second-line chemotherapy for castration-
and docetaxel-resistant prostate cancer (DRPC). Recent data suggest that carboplatin may …

Despite a survival benefit in the first‐line treatment of castrate‐resistant prostate cancer
(CRPC) with docetaxel, the prognosis remains limited. There are increasing options …

As recently as 2004, treatment options for men with metastatic castration-resistant prostate
cancer (mCRPC) were limited, with docetaxel the only approved agent conferring a survival …

188 Background: Abiraterone or enzalutamide are licensed for use post-docetaxel in
metastatic castrate resistant prostate cancer (mCRPC). Both target the androgen receptor …

Systemic therapy after first-line docetaxel in metastatic ca... : Current Opinion in Supportive and
Palliative Care Systemic therapy after first-line docetaxel in metastatic castration-resistant …

PURPOSE To present a summary of the recommendations for the treatment and follow-up
for metastatic castration-resistant prostate cancer (mCRPC) as acquired through a …

Objectives To report long‐term outcome survival analysis of docetaxel‐based chemotherapy
combined with dexamethasone in castration‐resistant prostate cancer patients (Japan …